115 related articles for article (PubMed ID: 37632156)
21. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma.
Gonsalves WI; Rajkumar SV; Gupta V; Morice WG; Timm MM; Singh PP; Dispenzieri A; Buadi FK; Lacy MQ; Kapoor P; Gertz MA; Kumar SK
Leukemia; 2014 Oct; 28(10):2060-5. PubMed ID: 24618735
[TBL] [Abstract][Full Text] [Related]
22. Pretreatment
Abe Y; Narita K; Kobayashi H; Kitadate A; Miura D; Takeuchi M; O'uchi E; O'uchi T; Matsue K
Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1325-1333. PubMed ID: 30687892
[TBL] [Abstract][Full Text] [Related]
23. [Comparison of minimal residual disease in multiple myeloma patients detected by 8-color panels and next generation flow cytometry].
Wang XF; Wang TT; Zhang ZY; Zhou HX; Zhang YR; Chen WM; Geng CY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):512-517. PubMed ID: 31340626
[No Abstract] [Full Text] [Related]
24. [Diagnostic Value of CD27 Antigen in Patients with Multiple Myeloma].
Wang H; Liu L; Liu F; Chen LJ; Qu XY; Li JY; Wu YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Aug; 25(4):1069-1073. PubMed ID: 28823270
[TBL] [Abstract][Full Text] [Related]
25. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.
Gonsalves WI; Timm MM; Rajkumar SV; Morice WG; Dispenzieri A; Buadi FK; Lacy MQ; Dingli D; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
Leuk Res; 2016 May; 44():32-9. PubMed ID: 26994849
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of Association of Copy Number Alterations and Cell-Surface Expression Markers in Newly Diagnosed Multiple Myeloma Patients.
Dragoș ML; Ivanov IC; Mențel M; Văcărean-Trandafir IC; Sireteanu A; Titianu AA; Dăscălescu AS; Stache AB; Jitaru D; Gorgan DL
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886877
[TBL] [Abstract][Full Text] [Related]
27. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic Value of CD56 Expression in Newly Diagnosed Multiple Myeloma Patients and Its Related Factors].
Wang XX; Zhang LL; Wang T; Hou JX; Wang ZT; Qin H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):777-782. PubMed ID: 37356939
[TBL] [Abstract][Full Text] [Related]
29. [Immunophenotype characteristics of patients with multiple myeloma in different risk stratification].
Hu K; Wang J; Zhu MX; Wang YF; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1624-7. PubMed ID: 25543486
[TBL] [Abstract][Full Text] [Related]
30. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
[TBL] [Abstract][Full Text] [Related]
31. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.
Rawstron AC; Orfao A; Beksac M; Bezdickova L; Brooimans RA; Bumbea H; Dalva K; Fuhler G; Gratama J; Hose D; Kovarova L; Lioznov M; Mateo G; Morilla R; Mylin AK; Omedé P; Pellat-Deceunynck C; Perez Andres M; Petrucci M; Ruggeri M; Rymkiewicz G; Schmitz A; Schreder M; Seynaeve C; Spacek M; de Tute RM; Van Valckenborgh E; Weston-Bell N; Owen RG; San Miguel JF; Sonneveld P; Johnsen HE;
Haematologica; 2008 Mar; 93(3):431-8. PubMed ID: 18268286
[TBL] [Abstract][Full Text] [Related]
32. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma].
Yang PY; Liu MM; Fan HQ; Yang YP; Han W; Yu XY; Yue TT; Su KJ; Guo Q; Gao SJ; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):584-588. PubMed ID: 32397022
[No Abstract] [Full Text] [Related]
33. Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.
Santonocito AM; Consoli U; Bagnato S; Milone G; Palumbo GA; Di Raimondo F; Stagno F; Guglielmo P; Giustolisi R
Leuk Res; 2004 May; 28(5):469-77. PubMed ID: 15068900
[TBL] [Abstract][Full Text] [Related]
34. Flow cytometric aberrancies in plasma cell myeloma and MGUS - correlation with laboratory parameters.
Gupta S; Karandikar NJ; Ginader T; Bellizzi AM; Holman CJ
Cytometry B Clin Cytom; 2018 May; 94(3):500-508. PubMed ID: 29316245
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Relevance of Concordant Expression CD69 and CD56 in Response to Bortezomib Combination Therapy in Multiple Myeloma Patients.
ElMenshawy N; Farag NA; Atia DM; Abousamra N; Shahin D; Fawzi E; Ghazi H; El-Kott AF; Eissa M
Cancer Invest; 2021 Oct; 39(9):777-782. PubMed ID: 34344244
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma.
Han W; Jin Y; Xu M; Zhao SS; Shi Q; Qu X; Zhang R; Li J; Wu Y; Chen L
Hematology; 2021 Dec; 26(1):510-517. PubMed ID: 34314294
[TBL] [Abstract][Full Text] [Related]
37. The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model.
Cannizzo E; Carulli G; Del Vecchio L; Ottaviano V; Bellio E; Zenari E; Azzarà A; Petrini M; Preffer F
Am J Clin Pathol; 2012 Mar; 137(3):377-86. PubMed ID: 22338049
[TBL] [Abstract][Full Text] [Related]
38. Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of "normal" residual plasma cell analysis.
Pojero F; Casuccio A; Parrino MF; Cardinale G; Colonna Romano G; Caruso C; Gervasi F
Cytometry B Clin Cytom; 2015; 88(3):165-82. PubMed ID: 25529228
[TBL] [Abstract][Full Text] [Related]
39. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage.
Rawstron AC; Owen RG; Davies FE; Johnson RJ; Jones RA; Richards SJ; Evans PA; Child JA; Smith GM; Jack AS; Morgan GJ
Br J Haematol; 1997 Apr; 97(1):46-55. PubMed ID: 9136941
[TBL] [Abstract][Full Text] [Related]
40. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study.
Liu H; Yuan C; Heinerich J; Braylan R; Chang M; Wingard J; Moreb J
Leuk Lymphoma; 2008 Feb; 49(2):306-14. PubMed ID: 18231918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
